Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.74 USD
0.00 (0.00%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $1.75 +0.01 (0.57%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Cash flow Statements
Fiscal Year End for Ocuphire Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -9.99 | 17.89 | -56.69 | -24.62 | -8.64 |
Depreciation/Amortization & Depletion | 0.01 | 0.00 | 0.00 | 0.01 | -0.07 |
Net Change from Assets/Liabilities | 4.08 | -5.56 | 0.18 | 1.15 | 0.22 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.79 | 1.98 | 37.14 | 16.67 | -1.80 |
Net Cash From Operating Activities | -1.11 | 14.31 | -19.37 | -6.80 | -10.28 |
Property & Equipment | 0.00 | 0.00 | -0.10 | -1.48 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 2.01 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 3.11 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | -0.10 | 0.54 | 3.10 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 9.26 | 4.46 | 28.58 | 0.06 | 7.65 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 23.35 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | -0.54 | 0.54 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.28 | -0.13 | -1.51 | -2.29 | 0.00 |
Net Cash from Financing Activities | 8.98 | 3.79 | 27.61 | 21.12 | 7.65 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 7.87 | 18.10 | 8.14 | 14.86 | 0.48 |
Cash at Beginning of Period | 42.63 | 24.53 | 16.40 | 1.54 | 8.74 |
Cash at End of Period | 50.50 | 42.63 | 24.53 | 16.40 | 9.22 |
Diluted Net EPS | -0.46 | 0.87 | -3.82 | -5.28 | -8.72 |
Fiscal Year End for Ocuphire Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -9.99 | -5.19 | -10.75 | -5.79 |
Depreciation/Amortization & Depletion | NA | 0.01 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 4.08 | -4.58 | 5.84 | 1.31 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.79 | 4.10 | 2.25 | 0.83 |
Net Cash From Operating Activities | NA | -1.11 | -5.66 | -2.66 | -3.65 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 9.26 | 5.38 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.28 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 8.98 | 5.38 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 7.87 | -0.28 | -2.66 | -3.65 |
Cash at Beginning of Period | NA | 42.63 | 42.63 | 42.63 | 42.63 |
Cash at End of Period | NA | 50.50 | 42.35 | 39.98 | 38.99 |
Diluted Net EPS | NA | -0.19 | 0.25 | -0.24 | -0.28 |